Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
- Author:
Wei-lai XU
1
;
Jie JIN
;
Wen-bin QIAN
Author Information
1. Institute of Hematology, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
- Publication Type:Clinical Trial
- MeSH:
Aclarubicin;
adverse effects;
therapeutic use;
Adult;
Aged;
Cytarabine;
adverse effects;
therapeutic use;
Drug Combinations;
Female;
Harringtonines;
adverse effects;
therapeutic use;
Humans;
Male;
Middle Aged;
Myelodysplastic Syndromes;
drug therapy;
mortality;
Treatment Outcome;
Young Adult
- From:
Chinese Medical Journal
2010;123(1):108-110
- CountryChina
- Language:English
